Concepedia

Sergey Shcherbinin

SS

Statistics

Publications

56

Citations

7.9K

H-Index

30

Active since

2008

Affiliations

Eli Lilly (United States)(Current)

University of British Columbia

Eli Lilly (United Kingdom)

Indiana University School of Medicine

Indiana University – Purdue University Indianapolis

Sergey Shcherbinin is an author at Eli Lilly (United States) specializing in medicine, neurology, and neurodegenerative diseases.

Top concepts

Publications per year

2008–2025

56

Publications

56

Donanemab in Early Symptomatic Alzheimer Disease

John R. Sims, Jennifer A. Zimmer, Cynthia Evans et al. · JAMA · 2023 · 2.2K citations · Full text

Donanemab in Early Alzheimer’s Disease

Mark A. Mintun, Albert Lo, Cynthia Evans et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

Elisabeth H. Thijssen, Renaud La Joie, Amy Wolf et al. · Nature Medicine · 2020 · 767 citations · Full text

, , +13

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

Shorena Janelidze, Erik Stomrud, Ruben Smith et al. · Nature Communications · 2020 · 437 citations · Full text

Regional profiles of the candidate tau PET ligand <sup>18</sup> F-AV-1451 recapitulate key features of Braak histopathological stages

Adam J. Schwarz, Peng Yu, Bradley B. Miller et al. · Brain · 2016 · 426 citations · Full text

1–5 of 56